{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T23:48:24Z","timestamp":1775173704955,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.urolonc.2020.07.017","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T02:04:39Z","timestamp":1596765879000},"page":"132.e7-132.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Primary Ta high grade bladder tumors: Determination of the risk of progression"],"prefix":"10.1016","volume":"39","author":[{"given":"Fahad","family":"Quhal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"D'Andrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Soria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Abufaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadi","family":"Mostafaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Laukhtina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Sari Motlagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2020.07.017_bib0001","article-title":"Cancer statistics, 2020","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2020.07.017_bib0002","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.07.017_bib0003","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and Carcinoma In Situ) - 2019 Update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.07.017_bib0004","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2020.07.017_bib0005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","article-title":"Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Gu\u00e9rin: results of a retrospective multicenter study of 2451 patients","volume":"67","author":"Gontero","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.07.017_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.07.017_bib0007","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.07.017_bib0008","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/bjc.2013.372","article-title":"Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder","volume":"109","author":"Xylinas","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2020.07.017_bib0009","doi-asserted-by":"crossref","first-page":"8.e17","DOI":"10.1016\/j.urolonc.2017.08.027","article-title":"Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer","volume":"36","author":"Rieken","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2020.07.017_bib0010","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.eururo.2011.05.033","article-title":"The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: external validation of the EORTC risk tables","volume":"60","author":"Fernandez-Gomez","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.07.017_bib0011","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1442-2042.2008.02235.x","article-title":"Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association","volume":"16","author":"Kikuchi","year":"2009","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2020.07.017_bib0012","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.07.017_bib0013","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0022-5347(05)67973-6","article-title":"Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations","volume":"163","author":"Lebret","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.07.017_bib0014","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/bju.13354","article-title":"The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade\/Grade 3 bladder cancer treated with bacille Calmette-Gu\u00e9rin","volume":"118","author":"Gontero","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2020.07.017_bib0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4103\/0974-7796.163798","article-title":"Results of second transurethral resection for high-grade T1 bladder cancer","volume":"8","author":"Hashine","year":"2016","journal-title":"Urol Ann"},{"key":"10.1016\/j.urolonc.2020.07.017_bib0016","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/21681805.2013.769461","article-title":"High-grade non-muscle-invasive bladder cancer: is re-resection necessary in all patients before intravesical bacillus Calmette-Gu\u00e9rin treatment?","volume":"47","author":"Holm\u00e4ng","year":"2013","journal-title":"Scand J Urol"},{"key":"10.1016\/j.urolonc.2020.07.017_bib0017","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1100\/tsw.2011.29","article-title":"Role of re-resection in non-muscle-invasive bladder cancer","volume":"11","author":"Herr","year":"2011","journal-title":"Sci World J"},{"key":"10.1016\/j.urolonc.2020.07.017_bib0018","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.eururo.2013.07.007","article-title":"Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature","volume":"64","author":"Rink","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.07.017_bib0019","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.eururo.2017.04.015","volume":"72","author":"Soukup","year":"2017","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920303392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920303392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:20:00Z","timestamp":1761042000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920303392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1078143920303392"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.07.017","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary Ta high grade bladder tumors: Determination of the risk of progression","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}